Oramed Pharmaceuticals (ORMP) Return on Capital Employed (2011 - 2026)
Oramed Pharmaceuticals' (ORMP) quarterly Return on Capital Employed came in at 5.95% in Q1 2026, up 386.0% YoY from 1.23% in Q1 2025, and up 18.48% on a QoQ basis from 7.3% in Q4 2025.
Oramed Pharmaceuticals (ORMP) Return on Capital Employed (2011 - 2026) Analysis & Trends
Oramed Pharmaceuticals (ORMP) has 15 years of Return on Capital Employed data on file, last reported at 5.95% in Q1 2026.
- Quarterly Return on Capital Employed rose 386.0% year-over-year to 5.95% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 5.95% (up 386.0% YoY) and the FY2025 annual result came in at 8.67%, down 166.0% from the prior year.
- Return on Capital Employed advanced to 5.95% in Q1 2026, from 7.3% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 5.95% in Q1 2026 to a low of 35.12% in Q3 2022.
- A 5-year average of 15.24% and a median of 9.14% in 2023 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2023 — Return on Capital Employed soared 1831 bps — and 2025, when it sank 230 bps.
- Tracing ORMP's Return on Capital Employed over 5 years: stood at 27.45% in 2022, then jumped by 67 bps to 9.14% in 2023, then advanced by 9 bps to 8.27% in 2024, then grew by 12 bps to 7.3% in 2025, then grew by 18 bps to 5.95% in 2026.
- The last three Return on Capital Employed figures came in at 5.95% (Q1 2026), 7.3% (Q4 2025), and 7.03% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 26.09% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -50.93% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 7.88% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -6.85% |
| 10 | Oramed Pharmaceuticals | 196.17 Mn | 196.17 Mn | - | -4.71% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.71% |
| Mar 31, 2026 | -5.95% |
| Dec 31, 2025 | -7.30% |
| Sep 30, 2025 | -7.03% |
| Jun 30, 2025 | -9.06% |
| Mar 31, 2025 | -9.81% |
| Dec 31, 2024 | -8.27% |
| Sep 30, 2024 | -7.71% |
| Jun 30, 2024 | -6.76% |
| Mar 31, 2024 | -7.57% |
| Dec 31, 2023 | -9.14% |
| Sep 30, 2023 | -20.98% |
| Jun 30, 2023 | -18.80% |
| Mar 31, 2023 | -23.85% |
| Dec 31, 2022 | -27.45% |
| Sep 30, 2022 | -35.12% |
| Jun 30, 2022 | -30.66% |
| Mar 31, 2022 | -23.54% |
| Aug 31, 2021 | -33.90% |
| Nov 30, 2019 | -43.95% |